Syntimmune Names Jean-Paul Kress, M.D. as President and CEO
8 January 2018 - - US-based FcRn biology specialist Syntimmune, Inc. has appointed Jean-Paul Kress, M.D., as president and chief executive officer, the company said.
Kress, who will also serve as a director of the company, brings senior leadership experience in pharmaceutical and biotechnology firms, with a focus on operations and commercialization of innovative products addressing unmet medical needs across diverse disease indications.
David de Graaf, Ph.D., has stepped down from his position as CEO and resigned from the company's board of directors.
Syntimmune co-founder Laurence Blumberg, M.D., will continue to serve as Syntimmune's chief operating officer and as a member of the board.
Prior to joining Syntimmune, Kress served as executive vice president and president, international, and head of global therapeutic operations at Biogen Inc., overseeing the company's rare and specialty disease teams.
Previously, he was senior vice president, head of North America at Sanofi Genzyme, where he was instrumental in launching several therapeutic products, including dupilumab, the first biologic agent approved in atopic dermatitis.
Kress received an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in pharmacology and immunology from École Normale Supérieure in Paris.
Syntimmune is advancing novel therapies based on understanding of the biology of the neonatal Fc receptor.
Based upon pre-clinical models, FcRn functions as a core part of a central common pathway that enables abnormal IgG responses, making it a well-validated target for the treatment of IgG-mediated autoimmune diseases.